NCT04727320

The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: All
• Age: 30 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective study. We signed an informed consent form with patients with liver fibrosis and took tauroursodeoxycholic acid orally for half a year. After half a year, liver biopsy was performed using histopathology, immunohistochemistry, and polymerase chain reaction, Western blotting method was used to determine the expression level of fibrosis-related markers to verify the effect of taurodeoxycholic acid on patients with liver fibrosis.

Detailed description

Tauroursodeoxycholic acid is an effective component of bear bile, which has obvious curative effects in the treatment of gallstones and liver diseases. In recent years, the research field of tauroursodeoxycholic acid has been very active, and its chemical synthesis has also attracted much attention. The usage is swallowing with water before going to bed at night. It must be taken regularly, one capsule at a time (250mg), once a day. After 6 months of continuous use, liver biopsy was performed after 6 months. Telling the patient to swallow with water before going to bed at night. It must be taken regularly, one capsule at a time (250mg), once a day. After 6 months of continuous use, liver B-ultrasound biopsy was performed to observe the effect.

Conditions

• Liver Cirrhosis

Interventions

Type	Name	Description
DRUG	Tauroursodeoxycholic acid	Oral TUDCA, once a day, one tablet (250mg) at a time for 6 months
DRUG	Placebo	Oral placebo, once a day, one tablet at a time for 6 months

Timeline

• Start date: 2021-03-05
• Primary completion: 2021-07-30
• Completion: 2021-07-30
• First posted: 2021-01-27
• Last updated: 2021-03-09